143 related articles for article (PubMed ID: 8657920)
1. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose.
Dehdashti F; Siegel BA; Griffeth LK; Fusselman MJ; Trask DD; McGuire AH; McGuire DJ
Radiology; 1996 Jul; 200(1):243-7. PubMed ID: 8657920
[TBL] [Abstract][Full Text] [Related]
2. FDG-PET evaluation of indeterminate pancreatic masses.
Ho CL; Dehdashti F; Griffeth LK; Buse PE; Balfe DM; Siegel BA
J Comput Assist Tomogr; 1996; 20(3):363-9. PubMed ID: 8626891
[TBL] [Abstract][Full Text] [Related]
3. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions.
Aoki J; Watanabe H; Shinozaki T; Takagishi K; Ishijima H; Oya N; Sato N; Inoue T; Endo K
Radiology; 2001 Jun; 219(3):774-7. PubMed ID: 11376267
[TBL] [Abstract][Full Text] [Related]
4. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.
Nakamoto Y; Higashi T; Sakahara H; Tamaki N; Kogire M; Doi R; Hosotani R; Imamura M; Konishi J
Cancer; 2000 Dec; 89(12):2547-54. PubMed ID: 11135214
[TBL] [Abstract][Full Text] [Related]
5. Differentiating benign and malignant pulmonary lesions with FDG-PET.
Yang SN; Liang JA; Lin FJ; Kwan AS; Kao CH; Shen YY
Anticancer Res; 2001; 21(6A):4153-7. PubMed ID: 11911310
[TBL] [Abstract][Full Text] [Related]
6. 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET.
Zhang H; Tian M; Oriuchi N; Higuchi T; Watanabe H; Aoki J; Tanada S; Endo K
Nucl Med Commun; 2003 Mar; 24(3):273-9. PubMed ID: 12612468
[TBL] [Abstract][Full Text] [Related]
7. The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions.
Dimitrakopoulou-Strauss A; Strauss LG; Heichel T; Wu H; Burger C; Bernd L; Ewerbeck V
J Nucl Med; 2002 Apr; 43(4):510-8. PubMed ID: 11937595
[TBL] [Abstract][Full Text] [Related]
8. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
Inoue T; Kim EE; Wong FC; Yang DJ; Bassa P; Wong WH; Korkmaz M; Tansey W; Hicks K; Podoloff DA
J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
[TBL] [Abstract][Full Text] [Related]
9. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose.
Shreve PD; Grossman HB; Gross MD; Wahl RL
Radiology; 1996 Jun; 199(3):751-6. PubMed ID: 8638000
[TBL] [Abstract][Full Text] [Related]
10. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of F-18 FDG PET and 201Tl scintigraphy for detection of primary malignant bone and soft-tissue tumors.
Yamamoto Y; Kawaguchi Y; Kawase Y; Maeda Y; Nishiyama Y
Clin Nucl Med; 2011 Apr; 36(4):290-4. PubMed ID: 21368603
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive grading of musculoskeletal tumors using PET.
Adler LP; Blair HF; Makley JT; Williams RP; Joyce MJ; Leisure G; al-Kaisi N; Miraldi F
J Nucl Med; 1991 Aug; 32(8):1508-12. PubMed ID: 1869970
[TBL] [Abstract][Full Text] [Related]
13. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors.
Uematsu H; Sadato N; Ohtsubo T; Tsuchida T; Nakamura S; Sugimoto K; Waki A; Takahashi N; Yonekura Y; Tsuda G; Saito H; Hayashi N; Yamamoto K; Ishii Y
J Nucl Med; 1998 Mar; 39(3):453-9. PubMed ID: 9529291
[TBL] [Abstract][Full Text] [Related]
14. Head and neck cancer: detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose.
Lapela M; Grénman R; Kurki T; Joensuu H; Leskinen S; Lindholm P; Haaparanta M; Ruotsalainen U; Minn H
Radiology; 1995 Oct; 197(1):205-11. PubMed ID: 7568825
[TBL] [Abstract][Full Text] [Related]
15. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma.
Nieweg OE; Pruim J; van Ginkel RJ; Hoekstra HJ; Paans AM; Molenaar WM; Koops HS; Vaalburg W
J Nucl Med; 1996 Feb; 37(2):257-61. PubMed ID: 8667056
[TBL] [Abstract][Full Text] [Related]
16. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.
Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN
Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750
[TBL] [Abstract][Full Text] [Related]
17. Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis.
Wu H; Dimitrakopoulou-Strauss A; Heichel TO; Lehner B; Bernd L; Ewerbeck V; Burger C; Strauss LG
Eur J Nucl Med; 2001 Jun; 28(6):704-10. PubMed ID: 11440030
[TBL] [Abstract][Full Text] [Related]
18. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.
Boland GW; Goldberg MA; Lee MJ; Mayo-Smith WW; Dixon J; McNicholas MM; Mueller PR
Radiology; 1995 Jan; 194(1):131-4. PubMed ID: 7997539
[TBL] [Abstract][Full Text] [Related]
19. Utility of FDG-PET in differential diagnosis of benign and malignant fractures in acute to subacute phase.
Kato K; Aoki J; Endo K
Ann Nucl Med; 2003 Feb; 17(1):41-6. PubMed ID: 12691129
[TBL] [Abstract][Full Text] [Related]
20. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET.
Kole AC; Nieweg OE; Pruim J; Paans AM; Plukker JT; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
J Nucl Med; 1997 May; 38(5):692-6. PubMed ID: 9170429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
